

IN THE CLAIMS:

Please substitute the following amended claims for corresponding claims previously presented. A copy of the amended claims showing current revisions is attached.

C6 23. (Amended) The immunogen according to claim *16* wherein said ligand is an antibody, or Fab₂ or Fab fragment thereof.

C6 34. (Amended) The immunogen according to claim *16* wherein said ligand binds to a CCR5 binding site on gp120 and upregulates a CD4 binding site on gp120.

C7 6. (Amended) The immunogen according to claim *16* wherein said ligand upregulates a CCR5 and a CD4 binding site on gp120.

C8 10. (Amended) The immunogen according to claim *16* wherein said protein is in soluble form.

C8 11. (Amended) The immunogen according to claim *16* wherein said protein is associated with a cell vesicle or liposome.

17¹⁵. (Amended) The immunogen according to claim 18
wherein gp120, gp41 and said ligand are crosslinked.

17¹⁶. (Amended) An isolated immunogen comprising an HIV envelope protein bound to a ligand, which ligand upregulates at least one of the CD4 binding site and the CCR5 binding site on said protein,
wherein said protein is gp120 noncovalently bound to gp41, and

wherein said immunogen further comprises an HR-2 peptide bound to said protein.

Cancel claims 1, 2, 11, 14 and 18-27, without prejudice.

REMARKS

Reconsideration of this application and entry of the foregoing amendments are respectfully requested.

The title has been amended as requested by the Examiner.

The specification has been amended to include a single updated paragraph that makes reference to the provisional applications from which this case claims priority.